Perspective Therapeutics, Inc.

AMEX:CATX

Medical - Devices

Healthcare
$0.78 +0.50%

+$0.02 today

Market cap
$94.20M
Beta
1.73
P/E (TTM)
-0.0
EPS (TTM)
-$107.27
52W Low $1.96High $6.16

Volume 2.69M

Average 1.44M

CATX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Perspective Therapeutics, Inc.AMEX: CATX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $20.25M rose 41.3% year over year, behind the +76.6% change in trailing-twelve-month research & development. Sequentially, it fell 38.5% from the prior quarter. Over 3 fiscal years it compounded at +218.7% a year.

Context

  • Research & development amounted to 9526.6% of revenue in FY2025, up 6662.9 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +41.3% toward the trailing-twelve-month pace of +76.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$20.25M-38.5% QoQ
Last fiscal yearDec 2025
$84.22M+102.3% YoY
LTMMar 2026
$85.68M+76.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+41.3%——
1 year+102.3%——
3-year CAGR+218.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
84.22M USD
Year-over-year change
+102.3%
4-year CAGR
+139.0%

Research & Development vs competitors

How CATX compares with its peers on the latest reported figures

  • CATX's LTM Mar 2026 research & development of $85.68M is the 2nd highest of the 5 companies compared; the peer median is $24.47M.
  • Its year-over-year change of +76.6% is the 2nd highest of 5, against a peer median of +11.4%.
  • Research & development amounts to 13864.6% of revenue for CATX, versus a peer median of 33.6%.
CATX Competitors Peer median
Research & Development for CATX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$229.1M +8.2%+2.9%34.0%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$85.68M +76.6%+218.7%13864.6%
DCTHDelcath Systems, Inc.LTM Mar 2026$34.06M +124.4%+16.3%37.7%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$14.89M -1.7%-11.2%33.2%
SRTSSensus Healthcare, Inc.LTM Mar 2026$6.76M +14.7%+31.0%30.0%
Peer median (excluding CATX) $24.47M+11.4%+9.6%33.6%

Competitors are the stored peer set for CATX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2022
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.8M7.1M1.43M1.45M884K
Cost of Revenue6.18M5.47M000
Gross Profit4.62M1.63M1.43M(852K)(2.37M)
Gross Margin42.8%23.0%100.0%-58.6%-267.8%
Research & Development2.58M2.6M21.31M41.64M84.22M
Selling, General & Admin9.43M14.21M21.06M26.61M30.23M
Operating Expenses12.01M17.43M42.38M92.34M113.56M
Depreciation & Amortization248K344K981K2.31M3.25M
EBITDA(7.39M)(14.84M)(39.96M)10.46M(100.8M)
EBITDA Margin-68.5%-208.9%-2786.6%719.3%-11402.8%
Operating Income(7.39M)(15.18M)(40.94M)10.46M(113.56M)
Operating Margin-68.5%-213.7%-2855.0%719.3%-12846.6%
Interest Income119K1.12M934K10.52M8.11M
Interest Expense119K084K(48K)376K
Other Income / Expenses119K512K835K(91.84M)9.14M
Income Before Tax(7.27M)(14.67M)(40.11M)(81.38M)(104.43M)
Pre-Tax Margin-67.4%-206.5%-2796.8%-5596.7%-11813.1%
Income Tax Expense(119K)0(2.65M)(2.1M)(793K)
Net Income(7.15M)(14.67M)(46.51M)(79.28M)(103.12M)
Net Margin-66.3%-206.5%-3243.2%-5452.5%-11665.3%
EPS (Basic)(0.13)(0.27)(0.85)(1.23)(1.40)
EPS (Diluted)(0.13)(0.27)(0.85)(1.23)(1.40)
Weighted Avg Shares54.91M54.91M54.91M64.43M73.81M
Weighted Avg Shares (Diluted)54.91M54.91M54.91M64.43M73.81M

Perspective Therapeutics, Inc.

AMEX:CATX

Intrinsic Alpha fair value

Locked

Current Price

$0.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.